JP2020522278A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522278A5 JP2020522278A5 JP2020516792A JP2020516792A JP2020522278A5 JP 2020522278 A5 JP2020522278 A5 JP 2020522278A5 JP 2020516792 A JP2020516792 A JP 2020516792A JP 2020516792 A JP2020516792 A JP 2020516792A JP 2020522278 A5 JP2020522278 A5 JP 2020522278A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 30
- 102000036639 antigens Human genes 0.000 claims 30
- 108091007433 antigens Proteins 0.000 claims 30
- 239000012634 fragment Substances 0.000 claims 27
- 238000000034 method Methods 0.000 claims 10
- 230000035772 mutation Effects 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 206010061598 Immunodeficiency Diseases 0.000 claims 4
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000007813 immunodeficiency Effects 0.000 claims 4
- 230000000903 blocking effect Effects 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 102000009109 Fc receptors Human genes 0.000 claims 2
- 108010087819 Fc receptors Proteins 0.000 claims 2
- 101000989065 Homo sapiens Immunoglobulin heavy variable 7-4-1 Proteins 0.000 claims 2
- 102100029420 Immunoglobulin heavy variable 7-4-1 Human genes 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 230000003325 follicular Effects 0.000 claims 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 101001008315 Homo sapiens Immunoglobulin kappa variable 3D-20 Proteins 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 102100027403 Immunoglobulin kappa variable 3D-20 Human genes 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 1
- 241000590503 Melanitis Species 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 235000011941 Tilia x europaea Nutrition 0.000 claims 1
- 208000031737 Tissue Adhesions Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000003302 anti-idiotype Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 150000004676 glycans Chemical group 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 230000000796 hypoacidity effect Effects 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000023589 ischemic disease Diseases 0.000 claims 1
- 208000002741 leukoplakia Diseases 0.000 claims 1
- 239000004571 lime Substances 0.000 claims 1
- 238000002794 lymphocyte assay Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762515188P | 2017-06-05 | 2017-06-05 | |
| US62/515,188 | 2017-06-05 | ||
| US201862648114P | 2018-03-26 | 2018-03-26 | |
| US62/648,114 | 2018-03-26 | ||
| US201862673185P | 2018-05-18 | 2018-05-18 | |
| US62/673,185 | 2018-05-18 | ||
| PCT/US2018/035843 WO2018226580A2 (en) | 2017-06-05 | 2018-06-04 | Antibodies that specifically bind pd-1 and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020522278A JP2020522278A (ja) | 2020-07-30 |
| JP2020522278A5 true JP2020522278A5 (https=) | 2021-07-26 |
| JP7235733B2 JP7235733B2 (ja) | 2023-03-08 |
Family
ID=64562613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516792A Active JP7235733B2 (ja) | 2017-06-05 | 2018-06-04 | Ｐｄ－１に特異的に結合する抗体、及び使用方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10995149B2 (https=) |
| EP (1) | EP3634995A4 (https=) |
| JP (1) | JP7235733B2 (https=) |
| KR (1) | KR102692379B1 (https=) |
| CN (1) | CN110997712B (https=) |
| AU (1) | AU2018282094B2 (https=) |
| BR (1) | BR112019025574A2 (https=) |
| CA (1) | CA3065516A1 (https=) |
| CL (1) | CL2019003520A1 (https=) |
| CO (1) | CO2019013935A2 (https=) |
| CR (1) | CR20190550A (https=) |
| EC (1) | ECSP19086810A (https=) |
| IL (1) | IL271009B2 (https=) |
| MA (1) | MA52459A (https=) |
| MX (1) | MX2019014577A (https=) |
| MY (1) | MY199715A (https=) |
| NI (1) | NI201900123A (https=) |
| PE (1) | PE20200294A1 (https=) |
| PH (1) | PH12019502755A1 (https=) |
| TW (1) | TWI806873B (https=) |
| UA (1) | UA128035C2 (https=) |
| UY (1) | UY37761A (https=) |
| WO (1) | WO2018226580A2 (https=) |
| ZA (1) | ZA202000051B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3244313A1 (en) * | 2017-06-02 | 2025-06-13 | Bayer Healthcare Llc | Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| TWI890481B (zh) | 2018-02-09 | 2025-07-11 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
| AR114127A1 (es) | 2018-03-02 | 2020-07-22 | Lilly Co Eli | Anticuerpos agonistas contra pd-1 y usos de estos |
| CN114957475B (zh) * | 2018-09-26 | 2023-06-20 | 福州拓新天成生物科技有限公司 | 抗b7-h3的单克隆抗体及其在细胞治疗中的应用 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| WO2020163225A1 (en) * | 2019-02-05 | 2020-08-13 | Seattle Genetics, Inc. | Anti-cd228 antibodies and antibody-drug conjugates |
| US12466862B2 (en) * | 2019-06-04 | 2025-11-11 | Arizona Board Of Regents On Behalf Of Arizona State University | Plant-produced mABs against chikungunya virus with enhanced effector function and efficacy |
| JP6881658B2 (ja) * | 2019-07-05 | 2021-06-02 | 小野薬品工業株式会社 | Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療 |
| TW202118790A (zh) * | 2019-07-30 | 2021-05-16 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
| US20220332825A1 (en) | 2019-08-08 | 2022-10-20 | Ono Pharmaceutical Co., Ltd. | Bispecific protein |
| WO2021164722A1 (zh) * | 2020-02-21 | 2021-08-26 | 江苏恒瑞医药股份有限公司 | 抗il-2抗体、其抗原结合片段及其医药用途 |
| CR20220596A (es) | 2020-05-26 | 2023-01-23 | Boehringer Ingelheim Int | Anticuerpos anti-pd-1 |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| WO2022156773A1 (en) * | 2021-01-21 | 2022-07-28 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd | Protein complexes targeting il12 pathway |
| WO2022239820A1 (ja) * | 2021-05-13 | 2022-11-17 | 公益財団法人神戸医療産業都市推進機構 | 炎症性疾患を治療又は予防するための抗ヒトｐｄ－１アゴニスト抗体及びこれを含有する医薬組成物 |
| US20240279321A1 (en) | 2021-06-18 | 2024-08-22 | Therini Bio, Inc. | ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USE |
| WO2023070100A1 (en) * | 2021-10-21 | 2023-04-27 | Seismic Therapeutic, Inc. | Dual targeted immune regulating compositions |
| CN118284624A (zh) | 2021-11-19 | 2024-07-02 | 米罗生物有限公司 | Pd-1抗体及其用途 |
| KR20240137086A (ko) * | 2022-01-28 | 2024-09-19 | 조지아뮨 인코포레이티드 | Pd-1 작용제인 세포예정사 단백질 1에 대한 항체 |
| WO2024010861A2 (en) * | 2022-07-06 | 2024-01-11 | Santa Ana Bio, Inc. | Methods and compositions for treating autoimmune, allergic and inflammatory diseases |
| AU2023356930A1 (en) * | 2022-10-03 | 2025-05-15 | Therini Bio, Inc. | Multi-specific antigen binding proteins which bind human fibrin or fibrinogen ?c domain and vascular endothelial growth factor and methods of use |
| WO2024076993A2 (en) * | 2022-10-03 | 2024-04-11 | Therini Bio, Inc. | Multi-specific antigen binding proteins which bind human fibrin or fibrinogen ?c domain and vascular endothelial growth factor and methods of use |
| WO2024081686A2 (en) * | 2022-10-11 | 2024-04-18 | Ibio, Inc. | Epidermal growth factor receptor variant iii antibodies |
| KR20250122541A (ko) | 2022-10-25 | 2025-08-13 | 사이즈믹 테라퓨틱, 인코포레이티드. | 변이체 IgG FC 폴리펩티드 및 그 용도 |
| CN116854820B (zh) * | 2023-06-26 | 2024-02-06 | 华中科技大学同济医学院附属协和医院 | Pd-1非阻断性清除抗体及其用途 |
| WO2025151607A1 (en) * | 2024-01-10 | 2025-07-17 | Santa Ana Bio, Inc. | Methods and compositions for treating autoimmune, allergic and inflammatory diseases |
| WO2026008665A1 (en) | 2024-07-01 | 2026-01-08 | Vib Vzw | Binders of the pd-1•pd-l1 complex and their use |
| WO2026008009A1 (en) * | 2024-07-04 | 2026-01-08 | Xiamen Jiuheyipin Biopharmaceutical Co., Ltd. | Pd-1 targeting antibodies and uses thereof |
| CN120040594B (zh) * | 2025-02-21 | 2025-09-23 | 四川大学 | 一种靶向flt3基因编辑通用型car-t细胞的制备方法和应用 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| US8748356B2 (en) * | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9181342B2 (en) | 2008-09-12 | 2015-11-10 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| AU2009290544B2 (en) | 2008-09-12 | 2015-07-16 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| JP2012505654A (ja) | 2008-10-14 | 2012-03-08 | ヤンセン バイオテツク，インコーポレーテツド | 抗体をヒト化及び親和性成熟する方法 |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| TW201134488A (en) * | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| AU2011333738A1 (en) | 2010-11-24 | 2013-07-11 | Glaxo Group Limited | Multispecific antigen binding proteins targeting HGF |
| BR112014010580B1 (pt) | 2011-11-04 | 2021-01-12 | Zymeworks, Inc. | constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado |
| MX366910B (es) | 2013-03-15 | 2019-07-30 | Janssen Biotech Inc | Metodos de fabricacion para controlar el contenido de lisina c-terminal, galactosa y acido sialico en proteinas recombinantes. |
| CN104558177B (zh) | 2013-10-25 | 2020-02-18 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途 |
| SG11201604664PA (en) | 2013-12-12 | 2016-07-28 | Stemcentrx Inc | Novel anti-dpep3 antibodies and methods of use |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| KR102553870B1 (ko) * | 2014-03-27 | 2023-07-10 | 버드 락 바이오, 인크. | 인간 카나비노이드 1(cb1) 수용체 결합 항체 |
| KR102357893B1 (ko) * | 2014-08-05 | 2022-02-04 | 맵퀘스트 에스아 | Pd-1 에 결합하는 면역학적 시약 |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| DK3237446T3 (en) | 2014-12-22 | 2021-07-26 | Pd 1 Acquisition Group Llc | Anti-PD-1-antistoffer |
| TW201710286A (zh) * | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| HUE068868T2 (hu) | 2015-07-30 | 2025-02-28 | Macrogenics Inc | PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások |
| EP4458417A3 (en) | 2015-08-11 | 2025-02-19 | Wuxi Biologics Ireland Limited | Novel anti-pd-1 antibodies |
| AU2016317915B2 (en) | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| BR112018006237A2 (pt) * | 2015-09-29 | 2018-10-09 | Celgene Corp | proteínas de ligação a pd-1 e métodos de uso das mesmas |
| PE20181326A1 (es) | 2015-11-03 | 2018-08-20 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y sus usos |
| RU2656181C1 (ru) | 2016-07-13 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Анти-pd-1-антитела, способ их получения и способ применения |
| MY192158A (en) | 2016-09-14 | 2022-08-03 | Abbvie Biotherapeutics Inc | Anti-pd-1 antibodies and their uses |
| MX2019002867A (es) | 2016-09-19 | 2019-11-12 | Celgene Corp | Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1. |
| JP7348072B2 (ja) | 2017-06-01 | 2023-09-20 | コンピュジェン リミテッド | 三重併用抗体療法 |
| MX2020002612A (es) | 2017-09-07 | 2020-07-13 | Univ Res Inst Inc Augusta | Anticuerpos de la proteina de muerte celular programada 1. |
| AR114127A1 (es) | 2018-03-02 | 2020-07-22 | Lilly Co Eli | Anticuerpos agonistas contra pd-1 y usos de estos |
-
2018
- 2018-06-04 CR CR20190550A patent/CR20190550A/es unknown
- 2018-06-04 MY MYPI2019007135A patent/MY199715A/en unknown
- 2018-06-04 MA MA052459A patent/MA52459A/fr unknown
- 2018-06-04 PE PE2019002510A patent/PE20200294A1/es unknown
- 2018-06-04 MX MX2019014577A patent/MX2019014577A/es unknown
- 2018-06-04 KR KR1020207000242A patent/KR102692379B1/ko active Active
- 2018-06-04 UA UAA201912296A patent/UA128035C2/uk unknown
- 2018-06-04 CA CA3065516A patent/CA3065516A1/en active Pending
- 2018-06-04 US US15/997,148 patent/US10995149B2/en active Active
- 2018-06-04 BR BR112019025574-5A patent/BR112019025574A2/pt active Search and Examination
- 2018-06-04 WO PCT/US2018/035843 patent/WO2018226580A2/en not_active Ceased
- 2018-06-04 EP EP18813493.6A patent/EP3634995A4/en active Pending
- 2018-06-04 CN CN201880050979.XA patent/CN110997712B/zh active Active
- 2018-06-04 AU AU2018282094A patent/AU2018282094B2/en active Active
- 2018-06-04 JP JP2020516792A patent/JP7235733B2/ja active Active
- 2018-06-04 IL IL271009A patent/IL271009B2/en unknown
- 2018-06-05 UY UY0001037761A patent/UY37761A/es active IP Right Grant
- 2018-06-05 TW TW107119358A patent/TWI806873B/zh active
-
2019
- 2019-12-02 CL CL2019003520A patent/CL2019003520A1/es unknown
- 2019-12-04 NI NI201900123A patent/NI201900123A/es unknown
- 2019-12-05 PH PH12019502755A patent/PH12019502755A1/en unknown
- 2019-12-05 EC ECSENADI201986810A patent/ECSP19086810A/es unknown
- 2019-12-11 CO CONC2019/0013935A patent/CO2019013935A2/es unknown
-
2020
- 2020-01-03 ZA ZA2020/00051A patent/ZA202000051B/en unknown
- 2020-12-17 US US17/125,263 patent/US11746161B2/en active Active
-
2023
- 2023-06-08 US US18/331,280 patent/US20230340155A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020522278A5 (https=) | ||
| AU2020390926B2 (en) | Development and application of therapeutic agents for TSLP-related diseases | |
| JP6621778B2 (ja) | ＩＬ７受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用 | |
| US20210347904A1 (en) | Antibodies against tl1a and uses thereof | |
| AU2014226094B2 (en) | Antibodies that bind IL-23 | |
| JP2022088411A (ja) | Ｐｄ－１アゴニスト抗体およびその使用 | |
| JP2018537400A5 (https=) | ||
| RU2021133819A (ru) | Анти-lag-3 антитела | |
| JP2014532074A5 (https=) | ||
| JP2012531922A5 (ja) | Ｔｏｌｌ様受容体２へのヒト化抗体またはその抗原結合部位 | |
| JP2025500971A5 (https=) | ||
| WO2016197497A1 (zh) | 一种抗pd-1的单克隆抗体及其获得方法 | |
| RS59223B1 (sr) | Ne-antagonistička antitela usmerena protiv alfa lanca ekstracelularnog domena il7 receptora i njihova upotreba u lečenju kancera | |
| WO2021023274A1 (zh) | 人源化抗TNFα抗体及其用途 | |
| JP2016520595A5 (https=) | ||
| WO2021228091A1 (zh) | St2抗原结合蛋白 | |
| EP3606952A1 (en) | POLYPEPTIDES WITH MUTANT HUMAN IgG4 | |
| US20230272067A1 (en) | Human monoclonal antibodies against tigit for immune related diseases | |
| CN116234826A (zh) | Btla抗体 | |
| CN112480254B (zh) | 抗人白细胞介素-33受体的抗体及其制备方法和应用 | |
| CA3169980A1 (en) | Anti-il-2 antibody, and antigen-binding fragment thereof and medical use thereof | |
| TW202130365A (zh) | 對人類il-13及il-17具有結合特異性之多重特異性抗體 | |
| CN114829398A (zh) | 对人il-13具有结合特异性的抗体 | |
| EP2975056A1 (en) | Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity | |
| JP2024521904A (ja) | 抗ｔｒｅｍ－１抗体 |